Items tagged with Vaccines
Researchers working to find safest, effective TB vaccine (post)
SHANGHAI, China, Apr 21 – Researchers are now working on a strategy to introduce the safest and most effective Tuberculosis vaccines that reduce the disease worldwide through partnerships and creative mechanisms.
Study finds increasing size of elderly population as major contributor to TB infection in China (post)
A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to preliminary new research presented at the Fourth Global Forum on TB Vaccines in Shanghai. The researchers from the London School of Hygiene & Tropical Medicine found that developing a "post-infection" vaccine could reduce overall TB rates in China by almost a third by 2050.
Global partnerships key to eradicating TB (post)
Developing vaccines for tuberculosis represents a major global health priority and has been recognized as a critically important strategy to meet the World Health Organization’s ambitious goal of eliminating TB as a global health threat by 2035.
Massachusetts General Hospital launches phase II trial of BCG vaccine to reverse type 1 diabetes (post)
07/Jun/2015 - A phase II clinical trial testing the ability of the generic vaccine bacillus Calmette-Guérin (BCG) to reverse advanced type 1 diabetes has received approval from the U.S. Food and Drug Administration (FDA). The approval of this trial, which will shortly begin enrolling qualified patients, was announced today at the 75th Scientific Sessions of the American Diabetes Association (ADA) by Denise Faustman, MD, PhD, director of the Massachusetts General Hospital (MGH) Immunobiology Laboratory and principal investigator of the study.
Aeras, IDT Biologika form a strategic partnership with acquisition of Aeras’s manufacturing facility (post)
Rockville, MD., USA and Dessau, Germany, June 23, 2015 – Aeras and IDT Biologika today announced a strategic partnership that includes the acquisition of Aeras’s Biopharmaceutical Development Center (BDC) manufacturing facility by IDT.
Start of phase 2 trial in newborn infants in South Africa with VPM1002, a new vaccine developed by an Indo-German co-operation for prevention of tuberculosis (post)
08.07.2015 -- Enrollment of the first infant in a phase 2 clinical trial of a new vaccine to prevent tuberculosis (TB) has successfully started. VPM1002, the most advanced new TB vaccine in clinical development, will help curtail spread of life-threatening TB disease not only in endemic countries, but also in Europe. The vaccine candidate VPM1002 was recently out-licensed to Serum Institute of India Ltd. (SIIL), the world’s largest vaccine manufacturer according to number of doses sold. VPM1002 is developed by SIIL in collaboration with Vakzine Projekt Management GmbH (VPM). Mr. Adar C. Poonawalla, CEO and Executive Director of SIIL emphasizes that “TB still remains a major public health problem and only a new and more effective vaccine can help to restrict the expansion of multidrug-resistant and extremely drug-resistant TB and thus save the lives of millions of people each year. We are pleased with the start of this trial as it represents one more step in our efforts to continuously improve existing vaccines, and to make new, safe, efficacious and cost effective vaccines available to the world, especially for TB. This is also shown in our plans to start large trials with VPM1002 to address the challenges of relapsing TB in adults.”
Zambia: New vaccine inevitable to eliminate TB (post)
Tuberculosis (TB) remains a major public health problem that continues to claim millions of lives each year.
Effects of MVA85A vaccine on tuberculosis challenge in animals, a systematic review (post)
Liverpool, 9 September 2015 - A new systematic review of animal studies testing a vaccine for tuberculosis raises questions about whether the studies provided sufficient evidence to move into trials of children.
IDRI, Wellcome Trust team for tuberculosis vaccine trial in South Africa (post)
SEATTLE, September 17, 2015 -- Today, the Infectious Disease Research Institute (IDRI) and Wellcome Trust announce the start of a Phase 2a trial in South Africa of IDRI's tuberculosis (TB) vaccine candidate, which has been shown to both prevent and treat TB in preclinical studies in animal models. The Wellcome Trust awarded IDRI a $5.8 million/ £3.8 million grant to clinically assess the ability of IDRI's vaccine candidate to reduce TB recurrence after treatment. Even after successfully completing an anti-TB treatment regimen, patients may succumb to TB again, thereby threatening TB control programs by promoting spread and drug resistance. Prior Phase 1 clinical trials have shown that IDRI's TB vaccine candidate boosts immune responses that may protect against TB recurrence.
The novel vaccine candidate against tuberculosis, MTBVAC, initiates Phase 1B clinical trial (post)
The clinical trial will be conducted by South African Tuberculosis Vaccine Initiative (SATVI).
Biofabri, biotechnology company focusing on human health vaccines, will sponsor the Phase 1B clinical trial.
Page 4 of 32 · Total posts: 0
←First 3 4 5 Last→